Copyright
©The Author(s) 2020.
World J Gastroenterol. Apr 28, 2020; 26(16): 1888-1900
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1888
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1888
Figure 3 Clinical “stopping rules” of first and second line tyrosine kinase inhibitors.
RECIST: Response Evaluation Criteria for Solid Tumors; ECOG: Eastern Cooperative Oncology Group; RECIST: Response Evaluation Criteria for Solid Tumors criteria.
- Citation: Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900
- URL: https://www.wjgnet.com/1007-9327/full/v26/i16/1888.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i16.1888